All payments made in the preview are in test mode. Read more
Sign in
Back to Atlas
BSemi-durableStandard research/education caution
CMP-0233
Research

RAGE antagonist peptide (RAP)

Anti-inflammatory / Glycation

May reduce AGE/RAGE inflammatory signaling in experimental models

Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type
Peptide
Primary mechanism
Blocks RAGE-ligand interactions such as S100P/HMGB1/RAGE signaling
Primary market use
Inflammation / glycation research

Pharmacology

Molecular weight (Da)
1,272.56
Oral bioavailability
N/A (peptide; not oral)
Half-life
~5–60 min parent peptide; analogs may be longer
Route tags
SubQ; Injectable; route-dependent
Evidence level
Preclinical
Clinical status
Research
Value-for-money score
3 / 10

Reported protocol signal

No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Bioavailability and durability are poor unless delivered locally or modified

Educational and organizational assistant matrix. Not medical advice.

BioChrysalis Atlas is an educational, organizational, and tracking asset. It does not provide medical advice, diagnosis, treatment, prescriptions, or individualized dosing instructions. Compound profiles, protocol notes, and dosage fields summarize publicly discussed or source-listed reference patterns and are not recommendations. Consult a qualified healthcare professional before starting, stopping, or modifying any compound, medication, or supplement protocol.

© BioChrysalis · Evolve · Ascend · Transcend